Neurobiology

KIAA1199 expression and hyaluronan degradation colocalize in multiple sclerosis lesions

Mathieu Marella2, Laurence Jadin2, Gilbert A Keller2, Barry J Sugarman2, Gregory I Frost3, and H Michael Shepard2,4,1

2Drug Discovery Department, Halozyme Therapeutics, Inc., San Diego, CA 92121, USA, 3F1 Oncology, West Palm Beach, FL 33401, USA, and 4Biologics21.NET Consulting, San Diego, CA 92129, USA

1To whom correspondence should be addressed: Tel: +1-415-680-6868; e-mail: hms@biologics21.net

Received 26 May 2018; Revised 3 July 2018; Editorial decision 3 July 2018; Accepted 6 July 2018

Abstract

Modification of hyaluronan (HA) accumulation has been shown to play a key role in regulating inflammatory processes linked to the progression of multiple sclerosis (MS). The aim of this study was to characterize the enzymatic activity involved in HA degradation observed within focal demyelinating lesions in the experimental autoimmune encephalomyelitis (EAE) animal model. EAE was induced in 3-month-old female C57BL/6J mice by immunization with myelin oligodendrocyte glycoprotein 33–35 (MOG33–35) peptide. The mice were monitored for 21 days. Formalin-fixed paraffin-embedded tissue from control and EAE mice were labeled with an immunoadhesin against HA, antibodies against KIAA1199 and glial fibrillary acidic protein, a marker for astrocytes. In situ hybridization was conducted using a KIAA1199 nucleic acid probe. In histologic sections of spinal cord from EAE mice, abnormal HA accumulation was observed in the close vicinity of the affected areas, whereas HA was totally degraded within the focal loci of damaged tissue. KIAA1199 immunoreactivity was exclusively associated with focal loci in damaged white columns of the spinal cord. KIAA1199 was mainly expressed by activated astrocytes that invaded damaged tissue. Similar findings were observed in tissue from an MS patient. Here, we show that KIAA1199, a protein that plays a role in a HA degradation pathway independent of the canonical hyaluronidases such as PH20, is specifically expressed in tissue lesions in which HA is degraded. KIAA1199 expression by activated astrocytes may explain the focal HA degradation observed during progression of MS and could represent a possible new therapeutic target.

Key words: Astrocyte, CEMIP, hyaluronan, KIAA1199, multiple sclerosis

Introduction

Hyaluronan (HA), a widely distributed constituent of the extracellular matrix that accumulates in connective, epithelial and nervous tissues, is a nonsulfated glycosaminoglycan to which many physiologic functions have been ascribed. The latter include cellular migration and proliferation, tissue repair, tissue hydrodynamics, cancer progression and inflammatory processes (Hascall and Karamanos 2011; Jiang et al. 2011; Shepard 2015).

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) affecting ~2.5
millions of people worldwide (Pugliatti et al. 2002). It is characterized by an autoimmune response against the fully mature oligodendrocytes that provide myelin sheaths around axons. Demyelinated axons are unable to effectively propagate action potentials, resulting in neurologic deficits. Short-term remyelination can occur in MS lesions, transiently improving symptoms. Disease progression is accompanied by chronic remyelination failure, partially because of oligodendrocyte death and the inability of oligodendrocyte precursor cells (OPCs) to differentiate into mature myelinating cells (Plemel et al. 2017).

Maturation and differentiation of oligodendrocytes occur in distinct stages. OPCs constitute a primary stage of oligodendrogial cell maturation. They are relatively small fibroblastic cells that can migrate within the tissue and express specific cellular markers including platelet-derived growth factor receptor α (PDGFR-α) and nestin. OPCs differentiate into immature oligodendrocytes, best characterized by the expression of the myelination marker, O4 and reduced motility. Once the oligodendrocyte attaches to and covers portions of the axon, it is considered a fully differentiated cell that can synthesize large amounts of myelin basic protein (MBP), a major component of the myelin sheath. A fully mature oligodendrocyte can produce the myelin sheaths for several axons (Barateau and Fernandes 2014).

Mouse experimental autoimmune encephalomyelitis (EAE) is a widely used experimental model of human inflammatory demyelinating diseases because it recapitulates some of the events observed during MS (Steinman 1999). EAE is a CD4-positive, T-cell-mediated autoimmune disease in which, as in MS, the demyelinating lesions of the white matter exhibit abnormal accumulation of B cells, T cells, macrophages and activated astrocytes, a condition defined as astrocytosis (Boyle and McGee 1990; Ludwin et al. 2016). Astrocytosis is one of the hallmarks of all neuropathologies and especially neuroinflammatory events. In MS, astrocytes accumulate around damaged tissue, playing fundamental roles in disease progression (Brosnan and Raine 2013). However, they may also play a protective role by enhancing the immune responses that ultimately inhibit myelin repair but can also limit CNS inflammation and support axonal regeneration (Correale and Farez 2015). Astrocyte activation leads to regional loss of the blood–brain barrier and recruitment of pro-inflammatory immune cells via chemokine production.

HA synthesis or catabolism is crucial to OPC maturation, remyelination and immune cell activation (Back et al. 2005; Sloane et al. 2010; Lee-Sayer et al. 2015; Marella et al. 2017). Accumulation of HA fragments of different molecular weights is thought to affect disease progression. Little is known about the mechanisms underlying HA degradation and resynthesis in MS, although hyaluronidase (HYAL) activity has been postulated to contribute (Preston et al. 2013).

In contrast to previously published data, PH20 was not detected in the EAE model, although substantial HA degradation was observed (Preston et al. 2013; Marella et al. 2017). Thus, we sought to understand this phenomenon. KIAA1199 protein, also known as CEMP or HYBID, has recently been shown to bind and participate in the degradation of HA independently of the canonical HYALs (Abe et al. 2003; Yoshida et al. 2013). Based on its known properties (Yoshida et al. 2014; Chanmee et al. 2016), we hypothesized that the KIAA1199 protein could be involved in HA degradation associated with demyelinating lesions. This hypothesis was tested in the present study using the murine EAE model, with findings confirmed in human MS tissue samples.

### Results

**HA is focally degraded in damaged areas of the EAE mouse spinal cord**

Staining for HA was conducted on transverse sections of spinal cord from control and EAE mice. Control tissue displayed a homogeneous distribution of HA across the white matter of the section, whereas affected tissue from EAE mice showed increased HA accumulation in the proximal region of the lesion and decreased HA on the peripheral side, which coincided with the region of highest disease activity (Figure 1A–D). In sharp contrast to the distribution of HA seen in normal spinal cord (Figure 1A and B), extracellular HA appeared to be degraded within the peripheral (damaged) areas of the EAE mouse spine (Figure 1C and D), with clusters of high HA accumulation immediately adjacent to those lesions. When the HA intensity is compiled across the white column of the spinal cord, HA level in EAE mouse spines increased dramatically in the close vicinity of a damaged region but decreased abruptly at the site of cell infiltrates (Figure 1E).

Transverse sections of the spinal cord of EAE mice labeled with an anti-MBP antibody showed the expected specific loss of myelination and increases in cell number in different discrete locations of the spinal cord white columns (Supplementary data, Figure S1). Myelin and HA colabeling in spinal cord sections showed a similar pattern with a strong correlation between foci of demyelination and HA degradation (Supplementary data, Figure S2). A significant increase in the number of maturing OPCs (PDGFR-α-positive) and prematuring oligodendrocyte cells (O4-positive) was found in the surrounding damaged portions of the tissue in EAE spinal cords (Figure 2).

Deficiency of HA synthase-3 (HAS-3), and to a lesser extent, HAS-1 or HAS-2, is associated with altered neuronal activity and seizures in mice (Arranz et al. 2014). Thus, we explored whether increased expression of HAS-3 could be associated with damaged areas in the EAE spinal cord. Elevated HAS3 expression, detected exclusively in remaining myelinated axons, was located in the immediate vicinity of the damaged areas in EAE spinal cord (Supplementary data, Figure S3).

**KIAA1199 protein expression was colocalized within areas of HA degradation**

Others have reported that PH20 was selectively expressed in demyelinating lesions in mice with EAE (Preston et al. 2013). However, we were not able to detect PH20 expression in OPCs in normal nor demyelinated CNS of EAE mice (Marella et al. 2017). Therefore, immunofluorescence was used to determine whether a new HA-binding protein involved in HA depolymerization, KIAA1199 (Abe et al. 2003; Yoshida et al. 2013), was expressed within the damaged tissue. KIAA1199 immunoreactivity was observed only in the EAE-damaged white columns of the spinal cord (Figure 3, open arrows) in which HA was totally degraded. Control samples displayed a weak KIAA1199 nuclear staining of some motorneurons. The specificity of the positive immunolabeling was confirmed by in situ hybridization (ISH) using probes directed to portions of mRNA of the KIAA1199 gene. A clear positive correlation between the KIAA1199 probes and the anti-KIAA1199 antibody was observed in the damaged areas of the EAE spines, but no motorneuron staining was confirmed by KIAA1199 probes (Supplementary data, Figure S4). The immunolabeling for KIAA1199 was superimposable to the area of the tissue in which HA was completely degraded.

Reactive oxygen species (ROS) are soluble factors generated during inflammatory processes that can mediate HA degradation...
Expression and localization of KIAA1199 protein was assessed in vivo for up to 36 h. Within 12 h, primary astrocytes in culture began to express KIAA1199, and this expression continued to increase after 24 and 36 h of cytokine incubation (Figure 6).

In order to assess a potential functionality of KIAA1199 expression by the astrocytes, in vitro chemotaxis assays were performed. Primary cultures of mouse astrocytes were infected with lentivirus carrying short hairpin RNA (shRNA)-targeting KIAA1199 mRNA sequences. Expression of KIAA1199 protein was assessed by western blot on culture infected or not with the scramble or specific shRNA. Figure 7 shows that KIAA1199 expression occurred when the astrocytes were incubated with a mixture of pro-inflammatory cytokines and only astrocytes infected with the anti-KIAA1199 shRNA could not express the protein under similar conditions. The same cell cultures were used in a 3D chemotaxis assay in which the astrocytes were trapped in a HA-rich scaffold (HyStem-C). The migration of those cells was induced by a gradient of fetal bovine serum (FBS) diluted at 10% in DMEM culture medium. The migration of the cells was monitored during 48 h by recording the nuclei location of 20 randomly targeted cells (Figure 7). Over a period of 48 h when exposed to the FBS gradient, the naïve astrocytes and astrocytes conditioned with scrambled shRNA migrated an average of 74.5 and 68.1 μm, respectively, representing approximately 3.5 cell lengths. Within the same conditions, the cells exposed to the lentivirus carrying KIAA1199 shRNA migrated far less: 23.8 μm, representing 1.2 cell lengths. The specific inhibition of KIAA1199 reduced significantly the capacity of astrocytes to travel through this HA-rich scaffold.

KIAA1199 expression by activated astrocytes was also observed in human MS

Expression and localization of KIAA1199 protein was assessed in pons tissue from a normal individual and an MS patient. Sections of commercially available tissue of human pons were labeled for KIAA1199 and GFAP protein (Figure 8). MS tissue showed strong KIAA1199 immunoreactivity (Figure 8D); control tissue did not (Figure 8A). Signs of astrocytosis, such as hypertrophic GFAP-positive cells, were present. As seen in Figure 8F, positive staining for KIAA1199 colocalized with activated astrocytes. Costaining for HA and MBP showed a uniform distribution of HA and myelinating oligodendrocytes in the control sample, and an apparent concomitant degradation of HA and demyelination in the pons of the MS patient sample (Figure 9A–I).

KIAA1199 is expressed by activated astrocytes in vivo and in vitro

We visualized astrocytes with an anti-glial fibrillary acidic protein (GFAP) antibody and found that their number increased in the damaged spinal cord, although their overall distribution was not restricted to the damaged areas (Figure 4A–F). Axonal loss was confined within focal portions of the tissue presenting cellular infiltrates (Figure 4G–I).
Fig. 2. Oligodendrocytes were recruited and differentiated in the vicinity of the demyelinated areas. The different maturation steps of the oligodendrocytes were assessed in control (A–C, G–I) or EAE (D–F, J–L) mice lumbar spinal cords. Anti-platelet-derived growth factor receptor α (PDGFR-α) is expressed by oligodendrocyte precursor cells (OPCs). A high number of PDGFR-α-positive cells are labeled within the damaged areas of the EAE animal spinal cords (F, M). The positive O4 staining shows numerous premyelinated oligodendrocytes in the myelin oligodendrocyte glycoprotein (MOG)-treated spinal cord tissue (L, N). Statistical significance was evaluated by Student t test (*P < 0.05; **P < 0.001, compared with their respective controls, n = 3 control animals and n = 6 MOG-treated mice, three tissue sections per animal were evaluated; bar graphs represent the mean ± standard deviation).

Fig. 3. KIAA1199 is colocalized with HA-degraded areas in the EAE lesions. Transverse sections of the spinal cord of control and EAE mice were costained for KIAA1199 (A, D) and HA (B, E). (C) and (F) are the merged micrographs showing HA (green), KIAA1199 (red) and the DAPI counterstain (blue). KIAA1199 is found almost exclusively in the lesions of the EAE in which HA content is degraded (open arrows). KIAA1199 immunolabeling is mostly associated with cell structures (scale bar, 80 μm).
There was a dramatic change in HA distribution around and within focal lesions characteristic of MS damage in both human and EAE mice as compared with the respective controls. In controls and nonaffected samples, HA was distributed homogenously within the tissue. In contrast, a large amount of HA accumulated proximal to the immediate vicinity of the tissue lesions, while none was observed within the focal damage in the EAE mouse spinal tissue. One major feature linked to MS progression is the inability of oligodendrocytes to generate new myelin sheets. In EAE mice, we observed numerous PDGFR-α-positive OPCs near the damaged areas, while only a few PDGF-α-positive OPCs were observed in the white columns of control spinal cords. HAS-3 was overexpressed within the axonal processes proximal to the damaged areas and colocalized with high HA accumulation (Supplementary data, Figure S3). This strong accumulation of HA around the damaged areas could act as a physical barrier, circumventing the ongoing inflammatory processes to the least minimum space. High-molecular weight HA has been linked to anti-inflammatory effects through regulatory T cells (Itano et al. 1999; Bollyky et al. 2007).

Piao et al. (2013) reported that the HA receptor CD44 was expressed by OPCs and involved in the in vivo migration of those cells toward sites of high HA concentration, like those surrounding damaged lesions in the MS and EAE tissues in this study. Moreover, the authors reported that the loss of the HA–CD44 interaction resulted in the inhibition of OPC migration. Interestingly, we and others have demonstrated that OPC differentiation was inhibited by the presence of HA fragments (Back et al. 2005; Sloane et al. 2010; Marella et al. 2017). Therefore, the HA depolymerization and clearance that we observed within the damaged areas possibly inhibits OPC migration and contributes to their differentiation into myelinating cells.

Although it is generally accepted that HA is degraded in chronic demyelinated MS lesions and in acute lesions in EAE mice, the factors regulating this degradation remain poorly understood. Soltés et al. reported that ROS could result in HA cleavage (Soltés et al. 2006; Stern et al. 2007). In the EAE mice spinal cords, the presence of oxidative damage near tissue lesions indicates that ROS could have played a role in the observed HA depolymerization. However, the extent of 8-isoprostane-positive tissue did not match that of the focal HA-degraded areas. Conflicting results have been reported regarding the potential role of PH20 in MS models (Preston et al. 2013; Marella et al. 2017). Here, we demonstrated that both the KIAA1199 mRNA and protein colocalized almost exclusively within the damaged areas.
the damaged regions of the EAE spinal cord where HA was degraded and were expressed mostly by activated astrocytes. These results agree with the ascribed function of KIAA1199 to bind to high-molecular weight HA and mediate HA internalization and depolymerization (Yoshida et al. 2013, 2014; Chanmee et al. 2016). A growing body of evidence links the presence of KIAA1199 protein to inflammatory events. Soroosh et al. (2016) described the action of KIAA1199 overexpression in Crohn’s disease fibroblasts, while others have reported that the pro-inflammatory NF-kB pathway could positively influence the expression of KIAA1199 (Tak and Firestein 2001; Shostak et al. 2014). Here, we showed that KIAA1199 expression by astrocytes in vitro depends on exposure to pro-inflammatory cytokines. In vitro migration assays were carried out to characterize the physiologic advantage of KIAA1199 expression. Astrocytes appear to use KIAA1199 expression to increase their migration through HA-rich scaffolds. It has been reported that astrocytes could play opposing roles at sites of MS lesions by engaging in a protective phenotype or by exacerbating ongoing neuroinflammation (Correale and Farez 2015). Further research is needed to determine whether a therapeutic intervention aimed at decreasing KIAA1199 would help promote remyelination, as KIAA1199-driven HA degradation may be a key event promoting OPC maturation and enhancing myelin repair in MS.

**Materials and methods**

**Induction of EAE in mice**

EAE was induced and monitored for 21 days in 3-month-old female C57BL/6J mice (Jackson Laboratories, Bar Harbor, MA) by immunization with myelin oligodendrocyte glycoprotein 33–35 (MOG33–35) peptide (Hooke Laboratories, Lawrence, MA). On experimental day 0, the mice received two subcutaneous injections of 100 μL each of a solution of 1 mg/mL MOG33–35 peptide emulsified in complete Freund’s adjuvant. An intraperitoneal dose of 200 ng pertussis toxin was administered within 2 h of the MOG33–35 peptide injection and another was administered 24 h later. EAE symptoms were evaluated daily during study days 8–21. At day 21, all MOG-injected mice presented partial to complete hind limb paralysis (mice were no longer able to maintain posture of the rump and/or presented complete loss of movement of the hind limb).

**Immunofluorescence labeling**

Tissue samples were harvested from control and EAE mice at study day 21 and processed to formalin-fixed paraffin-embedded (FFPE) tissue blocks. Five-micrometer sections were labeled with antibodies after ethanol-based rehydration and heat-mediated antigen retrieval. Endogenous peroxidase activity was inhibited by incubating samples in an aqueous solution of 3% H2O2 for 20 min at ambient temperature. Tissue sections were blocked in phosphate-buffered saline (PBS) containing 10% goat serum for 30 min at ambient temperature. Primary antibodies were incubated overnight at 4°C in PBS containing 10% goat serum: anti-mouse MBP (Covance, Princeton, NJ; [SMI-94R], 1/1000); rabbit anti-PDGFR-α (LSBio, Seattle, WA; [LS-C414372], 14 μg/mL); mouse anti-O4 (Chemicon/Millipore, Burlington, MA; [MAB345], 1/100); rabbit anti-HAS3 (Santa Cruz Biotechnology, Dallas, TX; H64 [SC-66917], 1/100); anti-HA immunoadhesin (Halozyme Therapeutics, San Diego, CA; [HTI-601], 1/600) (Jadin et al. 2014); goat anti-8-epi-PGF2α (8-
isoprostane) (Oxford Biomedical Research, Rochester Hills, MI; [IS20], 1/300); rabbit anti-KIAA1199 (Aviva BioSystems, San Diego, CA; [ARP42526.P050], 1/400); mouse anti-neurofilament (SMI-32) (Abcam, Cambridge, UK; [Ab24574], 1/300); mouse anti-GFAP (Chemicon/Millipore, Burlington, MA; [MAB360], 1/300). After three washes of 3 min each with PBS containing Tween-20 0.05%, secondary antibodies (conjugated to Alexa Fluor®488 or Alexa Fluor®594) were applied to detect immunolabeling. Slides were mounted in Vectashield plus DAPI mounting medium (Vector Laboratories, Burlingame, CA). Representative photomicrographs were digitally captured with 5×, 20× and 40× objectives using an Axioskop microscope (Carl Zeiss, Oberkochen, Germany) equipped with a SPOT Pursuit™ camera (SPOT Imaging Solutions, Sterling Heights, MI).

In situ hybridization
Tissue was sectioned from FFPE blocks and used within 48 h. ISH was performed using an RNAscope 2.5 HD Assay-RED (ACDBio, Newark CA; [310036]) according to manufacturer instructions. The KIAA1199 nucleic acid probe used was specific for mouse CEMIP (Mm-Cemip, ACDBio [438231]).

Primary astrocytes shRNA transfection and migration assay
Primary astrocyte cells were generated from newborn C57BL6 mice meninges-free cortices (Marella and Chabry 2004). Astrocyte cultures contained >99% GFAP-positive cells. In order to “silence” KIAA1199 expression, primary astrocyte cell cultures were infected with batches of KIAA1199 shRNA lentivirus (Biosettia, San Diego, CA) as follows: 100 μL of each four batches of lentivirus carrying KIAA1199 shRNA (Table I) were mixed in 15 mL of culture medium and incubated with 10 × 10⁶ cells for 2 days. A total of 400 μL of the shRNA, generated by a random permutation of the CEMIP consensus sequence, was also mixed in 15 mL culture medium and incubated with 10 × 10⁶ cells. Additionally, each lentivirus construct carried a green fluorescent protein gene (GFP), allowing determination of the infection rate for the different astrocyte cultures (i.e., >96%).

Naive or shRNA-infected astrocytes were cultivated for 1 week. Next, 1 × 10⁵ cells were incubated with pro-inflammatory cytokines (TNF-α, 100 ng/mL; IL-1α, 50 ng/mL; IFN-γ, 0.5 mU/mL) in a 12-well plate for 24 h. Expression of KIAA1199 was assessed by western blot using a mixture of two antibodies (anti-KIAA1199, 1/1000 and anti-GFAP, 1/1000) diluted in PBS with 5% dry, nonfat milk.

Fig. 6. Primary mouse astrocytes incubated with a cytokine mix for 0, 12, 24 and 36 h were labeled for GFAP (A, D, G, J) and KIAA1199 (B, E, H, K). (C), (F), (I) and (L) are the merged micrographs that display KIAA1199 (green), GFAP (red) and the DAPI counterstain (blue). KIAA1199 expression was induced by the inflammatory cytokines in a time-dependent manner (scale bar, 50 μm).
Chemotaxis assays were performed in a 3D chemotaxis chamber (Ibidi, Fitchburg, WI) against a gradient of FBS diluted in DMEM. The different astrocyte cultures were embedded in an HA-rich scaffold (HyStem-C; ESI BIO, Alameda, CA). The scaffold was made following manufacturer instructions in the following proportions: glycosil/gelatin (1:1) mixture 74%, DMEM 7.5% and extra-link mix 18.5%. 1 × 10^6 astrocytes were combined into 75 μL scaffold; 6 μL were subsequently loaded into the central slot of the chemotaxis chamber. The gel was solidified for 30 min at 37°C, after which different combinations of culture medium supplemented with or without 10% FBS were added in the lateral compartments surrounding the cells. The chemotaxis chambers were equilibrated in the cell incubator for 60 min and placed onto a heated, motorized cell culture stage of an Olympus microscope. Cell migration was monitored for 48 h by imaging each chamber every 15 min (MetaMorph Research Imaging, Sunnyvale, CA). Migration was evaluated using

Fig. 7. shRNA-silencing KIAA1199 expression reduces astrocyte migratory capacities through hyaluronan (HA)-rich environment. (A) In order to visualize KIAA1199 shRNA ability to prevent protein expression, primary mouse astrocytes were incubated or not with a cytokine mix (TNF-α, IL-1α and INF-γ) for 24 h. Expression of KIAA1199 protein from astrocyte cultures preinfected or not with KIAA1199 shRNA was assessed by western blot. (1) Naive astrocytes; (2) astrocytes infected with scrambled shRNA; (3) astrocytes infected with KIAA1199 shRNA. (B) Chemotaxis assays of astrocytes infected with shRNA. Astrocytes were embedded in the HyStem-C HA-rich gel and subjected or not to a 10% FBS gradient in a 3D chemotaxis chamber. Cell migration was recorded for 48 h and plotted. Astrocytes migrated toward medium containing 10% FBS. (C) Histogram showing the euclidean distance in micrometers migrated by the different astrocytes cultures (**P < 0.001, one-way ANOVA).

Fig. 8. Activated astrocytes express KIAA1199 protein in the pons of an individual with multiple sclerosis (MS). Tissue sections from a control patient (A–C) or an MS patient (D–F), were costained for KIAA1199 (A, D) and GFAP (B, E). Merged panels (C) and (F) display KIAA1199 (green), GFAP (red) and the nuclei DAPI counterstain (blue). KIAA1199 expression was colocalized with GFAP-positive cells in MS samples (scale bar, 50 μm). Inset in panel (F) shows a high magnification of the composite image. Presence of the KIAA1199 protein within the astrocytes process is indicated by closed arrows.
the ImageJ cell tracker plugin (http://rsb.info.nih.gov/ij/plugins/track/track.html) and the migration tools software (Ibidi).

ISH in human tissue
Human tissue used in this study was obtained from a third-party vendor, who was responsible for obtaining the necessary consent.

Supplementary data
Supplementary data are available at Glycobiology online.

Funding
This work was supported by Halozyme Therapeutics, Inc.

Acknowledgements
The authors acknowledge Sheryl Garovillo for histology support. Medical writing and editorial assistance was provided by Leonard Lionnet, PhD, CMPP (Lev Medical Communications) and Lauryn Uribe. This work was funded by Halozyme Therapeutics.

Conflict of interest statement
The authors are or were all employees of Halozyme Therapeutics at the time each individual contribution was made to the study.

Author contributions
MM and LJ performed experiments; MM, GK, BJS, GIF and HMS designed and analyzed experimental data. MM, GK and HMS wrote the draft of this article. MM, LJ, GK, BJS and HMS reviewed and edited the manuscript.

Abbreviations
HA, hyaluronan; MS, multiple sclerosis; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; MOG, myelin oligodendrocyte glycoprotein; CNS, central nervous system; OPC, oligodendrocyte precursor cell;
PDGF \( \alpha \), platelet-derived growth factor receptor \( \alpha \), MBP, myelin basic protein; HVL, hyaluronidase; HAS-3, HA synthase-3; ROS, reactive oxygen species; TNF-\( \alpha \), tumor necrosis factor \( \alpha \), IL-10, interleukin 10; IFN-\( \gamma \), interferon \( \gamma \); PBS, phosphate-buffered saline; FFPE tissue, formalin-fixed paraffin-embedded tissue; PBS, phosphate-buffered saline; ISH, in situ hybridization; shRNA, short hairpin RNA

References

Abe S, Usami S, Nakamura Y. 2003. Mutations in the gene encoding KIAA1199 protein, an inner-eye protein expressed in Dieters’ cells and the fibrocytes, as the cause of nonsyndromic hearing loss. *J Hum Genet*. 48:564–570.

Arranz AM, Perkins KL, Irie F, Lewis DP, Hrabe J, Xiao F, Itano N, Kimata K, Hrabetova S, Yamaguchi Y. 2014. Hyaluronan deficiency due to Has3 knock-out causes altered neuronal activity and seizures via reduction in brain extracellular space. *J Neurosci*. 34:6164–6176.

Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, Luo NL, Banine F, Liu Y, Chang A et al. 2005. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. *J Neurosci*. 25:465–474.

Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, Wight TN, Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, Luo NL, Banine F, Liu Y, Chang A et al. 2005. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. *J Neurosci*. 25:465–474.

Boyle EA, McGeer PL. 1990. Cellular immune response in multiple sclerosis plaques. *Am J Pathol*. 137:575–584.

Brosnan CF, Raine CS. 2013. The astrocyte in multiple sclerosis revisited. *Glia*. 61:453–465.

Channee J, Ongton P, Itano N. 2016. Hyaluronan: A modulator of the tumor microenvironment. *Cancer Lett*. 375:20–30.

Correale J, Farez MF. 2015. The role of astrocytes in multiple sclerosis progression. *Front Neurol*. 6:180.

Hascall V, Karamanos N. 2011. Regulatory roles of hyaluronan in health and disease. *FEBS J*. 278:1411.

Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, Shimomura T, Hamaguchi M, Yoshida Y, Ohnuki Y et al. 1999. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. *J Biol Chem*. 274:25085–25092.

Jadin L, Huang L, Wei G, Zhao Q, Gelb AB, Frost GI, Jiang P, Shepard HM. 2014. Characterization of a novel recombinant hyaluronan binding protein for tissue hyaluronan detection. *J Histochem Cytochem*. 62:672–683.

Jiang D, Liang J, Noble PW. 2011. Hyaluronan as an immune regulator in human diseases. *Phys Rev*. 91:221–264.

Lee-Sayer SS, Dong Y, Arif AA, Olsson M, Brown KL, Johnson P. 2015. The where, when, how, and why of hyaluronan binding by immune cells. *Front Immunol*. 6:150.

Ludwig MK, Rao VTS, Moore CS, Antel JP. 2016. Astrocytes in multiple sclerosis. *Mult Scler*. 22:1114–1124.

Marella M, Chalhy J. 2004. Neurons and astrocytes respond to prion infection by inducing microglia recruitment. *J Neurosci*. 24:620–627.

Pavel JH, Wang Y, Duncan ID. 2013. CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord. *Glia*. 61:361–367.

Praticò D, FitzGerald GA. 1996. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. *J Biol Chem*. 271:8919–8924.

رونونوستر م، صحرنی، گوگر، وولبیک هی، هیدربرد ژی، رونکاراتی پ، هننی، لادانگ آ و سایر. 2014. NF-kB-induced KIAA1199 promotes survival through EGFR signalling. *Nat Commun*. 5:5232.

Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. 2010. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. *Proc Natl Acad Sci USA*. 107:11555–11560.

Soroosh A, Alberio S, West GA, Willard B, Fiocchi C, de la Motte CA. 2016. Crohn’s disease fibroblasts overproduce the novel protein KIAA1199 to create proinflammatory hyaluronan fragments. *Cell Mol Gastroenterol Hepatol*. 2:358–368.e4.

Steinman L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. *Neuron*. 24:511–514.

Stern R, Kogan G, Jedrzejas MJ, Soltes L. 2007. The many ways to cleave hyaluronan. *Biotechnol Adv*. 25:537–557.

Tak PP, Firestein GS. 2001. NF-kB: a key role in inflammatory diseases. *J Clin Invest*. 107:7–11.

Yoshida H, Nagaoka A, Kusaka-Kikushima A, Tobishii M, Kawabata K, Sato T, Sakai S, Sugiyama Y, Enomoto H, Okada Y et al. 2013. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. *Proc Natl Acad Sci USA*. 110:5612–5617.

Yoshida H, Nagaoka A, Nakamura S, Tobishii M, Sugiyama Y, Inoue S. 2011. Hyaluronan-depolymerization of KIAA1199 to create proinflammatory hyaluronan. *Biotechnol Adv*. 25:537–557.

Šoltés L, Mendichi R, Kogan G, Schiller J, Stankovska M, Arnhold J. 2006. Degrading action of reactive oxygen species on hyaluronan. *Biomacromolecules*. 7:659–668.